Suggested remit - To appraise the clinical and cost effectiveness of lisocabtagene maraleucel within its marketing authorisation for treating large B-cell Lymphoma after at least 2 therapies
Status In progress
Process STA 2018
ID number 1444

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
31 October 2019 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies. Please note that following on from advice received from the company further information regarding the timelines of this appraisal will be available in due course.
29 May 2019 - 26 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 May 2019 In progress, Referred 24 April 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance